Risk-stratified analysis of pasireotide for patients undergoing pancreatectomy.
June S PengDaniel JoyceMaureen BradyAdrienne GromanKristopher AttwoodBoris KuvshinoffSteven N HochwaldMoshim KukarPublished in: Journal of surgical oncology (2020)
Pasireotide administration after pancreatectomy was not associated with a decrease in CR-POPF, even when patients were stratified by FRS.